Bio-Techne (TECH) Stock Forecast & Price Target

Bio-Techne has demonstrated a robust financial performance, with a notable 9% organic growth in FQ2'25 driven by increased investments from the pharma and biotech sectors, contributing to a revenue beat of approximately 4%. The company benefits from a balanced revenue distribution, with its Protein Sciences segment growing by 8% year-over-year and the Diagnostics and Spatial Bio segment increasing by 12% year-over-year, indicating strength across key product lines. Furthermore, positive sector dynamics in cell therapy and biopharma suggest that demand is likely to remain strong, signaling a favorable outlook for continued growth and potential margin expansion moving forward.

Bio-Techne faces significant challenges that contribute to a negative outlook, particularly as demand for its current and future offerings may fall short of projections, leading to potential revenue declines. Additionally, ongoing supply chain issues have resulted in elevated inventories and diminished equipment sales, compounded by a slowdown in small biotech purchasing, which could further impact earnings. The competitive landscape, characterized by larger and better-financed rivals, combined with macroeconomic uncertainties and an unclear path to achieving aggressive long-range growth targets under new leadership, heightens the risk of declining revenue and profitability.